Hydroxychloroquine COVID-19 prevention trials incomplete: WHO


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ hydroxychloroquine-covid19-prevention-trials-incomplete-who
Decades-old malaria and rheumatoid arthritis drug, hydroxychloroquine has been at the center of political and scientific controversy.

Hydroxychloroquine can be precluded as a treatment for hospitalized COVID-19 patients - yet the World Health Organization said Thursday it knew about progressing preliminaries into its incentive as a precaution measure.

A decades-old intestinal sickness and rheumatoid joint pain tranquilize, hydroxychloroquine has been at the focal point of political and logical discussion.

On Wednesday, the WHO chose to end its preliminaries of the medication for novel coronavirus patients in the emergency clinic, after proof from its own work and others that it had no impact on decreasing the death rate.

Yet, the UN wellbeing office said Thursday that proof from non-WHO preliminaries into whether it may or probably won't be valuable in forestalling against the infection had not yet finished up.

"To the extent the utilization of hydroxychloroquine for prophylaxis or counteraction of COVID-19 - either previously or after the presentation - the final word isn't yet out," WHO boss researcher Soumya Swaminathan told a virtual question and answer session.

"There are some acceptable and huge preliminaries going on, and we trust those will be finished with the goal that we have the sort of proof that we have to ensure that patients get the medications which help - and don't get drugs which don't help."

Hydroxychloroquine has been touted as a potential treatment for the new coronavirus by prominent figures, including US President Donald Trump.

The medication has been remembered for a few randomized clinical preliminaries - thought about the best quality level for clinical examination - yet the WHO said the proof had driven it to call time on its own preliminaries.

"What is clear presently is hydroxychloroquine doesn't have - we know without a doubt now - doesn't affect the infection in mortality in hospitalized COVID-19 patients," said Swaminathan, an Indian pediatrician.

"Where there is as yet a hole is: does it have any job whatsoever in anticipation, or in limiting the seriousness in early contamination? We don't realize that, up 'til now," she said.

Hydroxychloroquine is being tried on social insurance laborers and others with an elevated introduction to the infection in huge, randomized preliminaries.

Tags : #HCQ #COVID-19 #WHO #Trials

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026